Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Allergen immunotherapy: A practice parameter third update

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Seema S. Aceves, MD, PhD Journal of Allergy and Clinical Immunology

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy Justin M. Skripak, MD, Scott D. Nash, MD, Hannah.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? Ting Seng Tang, MBBS, Thomas.

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome Sophia Kim, MD, Gautham Marigowda, MD, Eyal Oren, MD, Elliot.

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Reply Journal of Allergy and Clinical Immunology

Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation Zuotao Zhao, MD, PhD, Sascha Reimann, MD, Shan Wang, MD, Yuhan Wang, MD,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Is eczema really on the increase worldwide?

Ovalbumin content of influenza vaccines

Basophils and eosinophils in allergic rhinitis

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Effect of ingested H1 antihistamines on methacholine challenge

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial Michael Weschta, MD, Dagmar Rimek,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

Advances in the approach to the patient with food allergy

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

Risk of oral food challenges

Thunderstorm-related asthma attacks

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Alvaro A. Cruz, MD, Robert M

Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids Pota Christodoulopoulos, BSca,

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Measles and immunomodulation

Nasal challenge with allergen leads to maxillary sinus inflammation

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Environmental factors and eosinophilic esophagitis

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms Fuad M. Baroody, MD, Deanna Shenaq, BSc, Marcy DeTineo, BSN, JiangHong Wang, MD, Robert M. Naclerio, MD Journal of Allergy and Clinical Immunology Volume 123, Issue 6, Pages 1342-1348 (June 2009) DOI: 10.1016/j.jaci.2009.03.015 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study design. The timeline appears at the bottom. The 3 arrows labeled AG denote the 3 consecutive allergen challenges performed on 3 consecutive days while patients were still on intranasal treatment. During each of these challenges, the subjects were challenged with the diluent for the allergen extract, followed 10 minutes later by challenge with either ragweed or grass antigen extracts. All challenge solutions (diluent or allergen) were placed on the nasal septum by using filter paper discs. Journal of Allergy and Clinical Immunology 2009 123, 1342-1348DOI: (10.1016/j.jaci.2009.03.015) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 The effect of FFNS on the sneezing response after allergen challenge. The x-axis shows the time scale and pretreatment. Net change from diluent is depicted as individual data (n = 20). The solid bars represent median levels. The dashed line represents the priming response. †P ≤ .03 vs day 1, illustrating priming, and ∗∗P < .01 and ∗P < .03 vs placebo, demonstrating the inhibitory effect of active treatment. FF, Fluticasone furoate nasal spray; PL, placebo. Journal of Allergy and Clinical Immunology 2009 123, 1342-1348DOI: (10.1016/j.jaci.2009.03.015) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 The effect of FFNS on contralateral nasal secretion weights after allergen challenge. The x-axis shows the time scale and pretreatment. Net change from diluent is depicted as individual data (n = 20). The solid bars represent median levels. The dashed line represents the priming response. †P ≤ .04 vs day 1 and day 2, illustrating priming, and ∗P < .04 vs placebo, demonstrating the inhibitory effect of active treatment. FF, Fluticasone furoate nasal spray; PL, placebo. Journal of Allergy and Clinical Immunology 2009 123, 1342-1348DOI: (10.1016/j.jaci.2009.03.015) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 The effect of FFNS on the total eye symptom score after allergen challenge. The x-axis shows the time scale and pretreatment. Net change from diluent is depicted as individual data (n = 20). The solid bars represent median levels. The dashed line represents the priming response. †P ≤ .04 vs day 1, illustrating priming, and ∗∗P ≤ .01 vs placebo, demonstrating the inhibitory effect of active treatment. FF, Fluticasone furoate nasal spray; PL, placebo. Journal of Allergy and Clinical Immunology 2009 123, 1342-1348DOI: (10.1016/j.jaci.2009.03.015) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 The effect of FFNS on the percentage of eosinophils in nasal scrapings. The x-axis shows the time scale and pretreatment. Percent eosinophils in scrapings obtained at the beginning of each challenge are depicted as individual data (n = 20). The solid bars represent median levels. The dashed line represents the priming response. ∗∗P ≤ .01 and ∗P ≤ .05 vs placebo, demonstrating the inhibitory effect of active treatment. FF, Fluticasone furoate nasal spray; PL, placebo. Journal of Allergy and Clinical Immunology 2009 123, 1342-1348DOI: (10.1016/j.jaci.2009.03.015) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions